Cargando…
Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19
Autor principal: | Abraham, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202318/ https://www.ncbi.nlm.nih.gov/pubmed/35675183 http://dx.doi.org/10.1056/NEJMe2205563 |
Ejemplares similares
-
Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children
por: Zheng, Zhe, et al.
Publicado: (2022) -
Chimeric antibodies with extended half-life in ferrets
por: Nesspor, Thomas C, et al.
Publicado: (2014) -
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin
por: Roy, Chad J., et al.
Publicado: (2020) -
1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
por: Mahoney, Kathryn, et al.
Publicado: (2023) -
Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis
por: Laufer, Rachel S., et al.
Publicado: (2023)